Thrombolytic therapy has been recognized as a significant improvement in the management
of acute myocardial infarction. Thrombolytic agents however have been limited by short half …

Tissue-type plasminogen activator (t-PA), a 65 kDa member of the chymotrypsin family of
serine proteases, catalyzes the rate-limiting step in the endogenous fibrinolytic cascade …

Plasminogen activators have immense clinical significance as thrombolytic agents for
management of stroke and myocardial infarction. Tissue-type plasminogen activator (tPA) is …

The novel recombinant plasminogen activator (rPA)(BM 06.022) is a mutant of tissue-type
plasminogen activator expressed in escherichia coli which can be given as a bolus because …

Thrombotic complications of cardiovascular disease are a main cause of death and disability
and, consequently, thrombolysis could favorably influence the outcome of such life …

Thrombolysis today has become a routine option not only in the treatment of acute
myocardial infarction but also in many other manifestations of thromboembolic disease. Until …

Thrombi, whatever their locations or etiologies, are to some extent composed of and held
together by fibrin. Fibrin is formed by the action of thrombin on soluble fibrinogen and is the …

Tissue-type plasminogen activator (tPA) catalyzes the rate-limiting initial step in the
fibrinolytic cascade. Systemic infusion of tPA has become the standard of care for acute …

Thrombolytic therapy of acute myocardial infarction is based on the premise that coronary
artery thrombosis is its proximate cause. Rupture of atheromatous plaque leads to occlusive …

Tissue Plasminogen Activator - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog …